Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Create a living biobank of PDOs from Stage I-III lung cancer patients.
- Lung Neoplasm
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure.
- Diagnosis of lung cancer or lung mass or lymphadenopathy that will undergo tumor resection as part of standard of care
- Any clinical stage
- Adult patients ≥18 years of age
- Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history
- At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.
- Study Type
- Observational Model
- Time Perspective
- The University of Texas Health Science Center at San Antonio
Study ContactJosephine Taverna, MD
Creation a living biobank of PDOs from Stage I-IV lung cancer patients (n=50). We selected enrollment of at least 50 patients so that they can be risk stratified based on lung tumor type, staging and we plan to store these PDOs in biobank for future experiments. For each patient, tumor specimens will be collected at time of their surgery. No specific therapeutic intervention or treatment is provided as part of this study.
1. Establishment and culture of PDOs from lung cancer tumor specimens. PDOs will be biobanked for future experiments.
2. Lung organoids and CTCs will also be cultured and used to study baseline tumor characteristics using histology, immunohistochemistry, atomic force measurements; as well as, oncogenic signaling pathways and proteomic profile of lung organoids and CTCs derived from lung cancer patients (n>50).
3. Patient demographic information and data to be collected using a patient survey data sheet with treatment and survival history collected at pre-defined time period per the protocol schedule.